

waivers of time limits established by the FTR for completion of all aspects of relocation, temporary storage of household goods (HHG) shipments, house hunting trips (HHT), and time remaining in a second tour of duty upon return from renewal agreement travel (RAT), as set forth in the bulletins. The aforementioned bulletins, and the waiver provisions therein, were set to expire on March 13, 2021.

Given that the COVID-19 outbreak has continued to produce uncertainty and create difficulties for relocating individuals, GSA has decided to extend these waivers by rescinding Bulletins FTR 20-06 and FTR 21-02 and re-establishing the information therein by issuance of this new GSA Bulletin FTR 21-04 with a later expiration date. This GSA Bulletin FTR 21-04 can be viewed at <https://www.gsa.gov/ftrbulletins>.

Krystal J. Brumfield,

Associate Administrator, Office of Government-wide Policy.

[FR Doc. 2021-05257 Filed 3-12-21; 8:45 am]

BILLING CODE 6820-14-P

AGENCY FOR HEALTHCARE RESEARCH AND QUALITY

Request for Information on the Use of Clinical Algorithms That Have the Potential To Introduce Racial/Ethnic Bias Into Healthcare Delivery; Correction

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.

ACTION: Notice; correction.

SUMMARY: The Agency for Healthcare Research and Quality published a document in the **Federal Register** of March 5, 2021, concerning request for information on the Use of Clinical Algorithms That Have the Potential To Introduce Racial/Ethnic Bias Into Healthcare Delivery. The document was missing a URL link to the Effective Health Care website.

FOR FURTHER INFORMATION CONTACT: Anjali Jain, 301-427-1630.

SUPPLEMENTARY INFORMATION:

Correction

In the **Federal Register** of March 5, 2021, in FR Doc. 2021-04509, on page 12948, in the first column, correct the **ADDRESSES** caption to read:

ADDRESSES: Submissions should follow the Submission Instructions below. We prefer that comments be submitted electronically on the Effective Health Care website at <https://effectivehealthcare.ahrq.gov/products/algorithms-bias-healthcare-delivery/request-info>. Email submissions may also be sent to: epc@ahrq.gov.

Dated: March 10, 2021.

Marquita Cullom,

Associate Director.

[FR Doc. 2021-05281 Filed 3-12-21; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHAC); Correction

Notice is hereby given of a change in the meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHACHSPT); April 12, 2021, from 3:00 p.m. to 5:00 p.m., EDT, in the original FRN.

The web conference meeting was published in the **Federal Register** on February 26, 2021, Volume 86, Number 37, page 11777.

The web conference meeting is being corrected to update the summary and contact information and should read as follows: This meeting is open to the public.

SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC and the Health Resources and Services Administration (HRSA), announces the following meeting for the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHACHSPT). This business meeting is open to the public, limited only by audio and web conference lines (1000 audio and web conference lines are available). The public is welcome to listen to the meeting by accessing the telephone number 1-669-254-5252, and the passcode is 55572151 (1000 lines are available). The web conference access is <https://cdc.zoomgov.com/j/1606419940?pwd=V2krVkVXbGt>

[vVFdLbXV3N25PbTV4UT09](https://cdc.zoomgov.com/j/1606419940?pwd=V2krVkVXbGt), webinar ID: 160 641 9940 and passcode: ZeTt@2VL. Due to the nature and time limitations of the meeting, members of the public will not have an opportunity to provide oral comments, although written comments may be submitted prior to the meeting, or up to 10 business days after the meeting, to Staci Morris at smorris4@cdc.gov.

FOR FURTHER INFORMATION CONTACT: Staci Morris, MS, Public Health Advisor, Office of Policy, Planning and Partnerships, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, 1600 Clifton Road NE, Atlanta, GA 30329-4027, Telephone (404) 718-7479; smorris4@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2021-05217 Filed 3-12-21; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Lead Exposure and Prevention Advisory Committee (LEPAC)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Lead Exposure and Prevention Advisory Committee (LEPAC). This meeting is open to the public by teleconference but advance registration by April 30, 2021, is needed to receive the information to join the meeting. The registration link is https://rossstrategic.zoom.us/webinar/register/WN_1vfWQt1_TdSOj1Laoo8bIw.

DATES: The meeting will be held on May 14, 2021, from 9:00 a.m. to 4:30 p.m., EDT.

ADDRESSES: Register in advance at https://rossstrategic.zoom.us/webinar/register/WN_1vfWQt1_TdSOj1Laoo8bIw to receive information to join the meeting.

FOR FURTHER INFORMATION CONTACT: Ms. Perri Ruckart, Dr. P.H. (candidate), M.P.H., Designated Federal Officer, National Center for Environmental Health, CDC, 4770 Buford Highway, Atlanta, GA 30341, Telephone: (770) 488-3300; PRuckart@cdc.gov.

SUPPLEMENTARY INFORMATION:

Purpose: The Lead Exposure and Prevention Advisory Committee was established under Section 2203 of Public Law 114-322, the Water

Infrastructure Improvements for the Nation Act; 42 U.S.C. 300j–27, Registry for Lead Exposure and Advisory Committee. The Secretary, Department of Health and Human Services (HHS) and by delegation, the Director, CDC and Administrator, NCEH/ATSDR, are authorized under Section 2203 of Public Law 114–322 (42 U.S.C. 300j–27) to review research and Federal programs and services related to lead poisoning and to identify effective services and best practices for addressing and preventing lead exposure in communities.

The LEPAC is charged with providing advice and guidance to the Secretary, HHS, and the Director, CDC and Administrator, ATSDR, on (1) reviewing Federal programs and services available to individual communities exposed to lead; (2) reviewing current research on lead exposure to identify additional research needs; (3) reviewing and identifying best practices, or the need for best practices regarding lead screening and the prevention of lead poisoning; (4) identifying effective services, including services relating to healthcare, education, and nutrition for individuals and communities affected by lead exposure and lead poisoning, including in consultation with, as appropriate, the lead exposure registry as established in Section 2203 (b) of Public Law 114–322; and (5) undertaking any other review or activities that the Secretary determines to be appropriate.

Matters To Be Considered: The agenda will include discussions on the Federal Lead Action Plan, American Healthy Homes Survey II, a 40-Year National Health and Nutritional Examination Survey (NHANES) Analysis of lead data, the Blood Lead Reference Value (BLRV) Workgroup, and the 2020 Annual LEPAC Report. Agenda items are subject to change as priorities dictate.

Public Participation

Procedure for Oral Public Comment: The public comment period is scheduled on May 14, 2021, from 11:45 a.m. until 12:00 p.m. Individuals wishing to make a comment during the public comment period, please email your name, organization, and phone number by April 30, 2021, to LEPAC@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and

Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2021–05218 Filed 3–12–21; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC–2021–0025]

Advisory Committee on Immunization Practices (ACIP)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting and request for comment.

SUMMARY: In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. Time will be available for public comment.

DATES: The meeting will be held on May 5, 2021, from 11:00 a.m. to 5:00 p.m., EDT (times subject to change). Written comments must be received on or before May 5, 2021.

ADDRESSES: You may submit comments, identified by Docket No. CDC–2020–0025 by any of the following methods:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments.

- **Mail:** Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H24–8, Atlanta, GA 30329–4027, Attn: May ACIP Meeting.

Instructions: All submissions received must include the Agency name and Docket Number. All relevant comments received in conformance with the <https://www.regulations.gov> suitability policy will be posted without change to <https://www.regulations.gov>, including any personal information provided. For access to the docket to read background documents or comments received, go to <https://www.regulations.gov>.

Written public comments submitted 72 hours prior to the ACIP meeting will be provided to ACIP members before the meeting.

FOR FURTHER INFORMATION CONTACT:

Stephanie Thomas, ACIP Committee Management Specialist, Centers for

Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, 1600 Clifton Road NE, MS–H24–8, Atlanta, GA 30329–4027; Telephone: 404–639–8367; Email: ACIP@cdc.gov.

SUPPLEMENTARY INFORMATION:

Purpose: The committee is charged with advising the Director, CDC, on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under provisions of the Affordable Care Act, section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been approved by the Director of the Centers for Disease Control and Prevention and appear on CDC immunization schedules must be covered by applicable health plans.

Matters To Be Considered: The agenda will include discussions on dengue vaccine and rabies vaccines. No recommendation votes are scheduled. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda visit <https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html>.

Meeting Information: The meeting will be webcast live via the World Wide Web; for more information on ACIP please visit the ACIP website: <http://www.cdc.gov/vaccines/acip/index.html>.

Public Participation

Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on <https://www.regulations.gov>. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/near duplicate examples of a mass-mail